Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis
International Journal of Pharmacy Practice · 2025
DOI: 10.1093/ijpp/riaf090 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacy Practice, 2025. Verfasst von Anjana Shenoy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India. Hauptthemen laut MEDLINE: Gastrointestinal Diseases, Hedgehog Proteins, Antineoplastic Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
The Hedgehog pathway inhibitors (HPIs) are effectively used to treat basal cell carcinoma (BCC). Despite the benefits, HPIs are reported to cause various gastrointestinal adverse events (GIAEs). The study was conducted to detect possible safety signals of HPIs concerning GIAE through disproportionality analysis.
Methods
A retrospective case/non-case disproportionality analysis was performed in the USFDA Adverse Event Reporting System database using OpenVigil 2.1, a web-based pharmacovigilance tool. All the GIAEs reported due to the HPIs, like vismodegib, sonidegib, and glasdegib, were extracted and analysed. The reporting odds ratio (ROR) > 1 was considered the reporting threshold. Key findings The HPIs accounted for 6781 adverse events, with 1196 GIAEs distributed across vismodegib (18.56%), sonidegib (13.89%), and glasdegib (5.39%). A potential safety signal was portrayed with atrophic glossitis [ROR: 181.88 (95% CI: 72.73–454.83)] and ageusia [153.34 (141.20–166.52)] from vismodegib. The study identified concerns of dysgeusia [17.39 (11.72–25.81)] from sonidegib and hepatotoxicity [20.25 (9.02–45.46)] from glasdegib.
Conclusions
HPIs had triggered various types of GIAEs. Liver injuries were a safety concern for the HPI-treated patient, which was not listed by the USFDA. Further researches are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
- College of Professional Studies, Northeastern University, Boston, 02115 MA, United States.
- Department of Pharmacology, Faculty of Pharmacy, M S Ramaiah University of Applied Sciences, Bengaluru 560054, India.
- Pharmacy Services Department, Johns Hopkins Aramco Healthcare, Dhahran 34465, Saudi Arabia.
- Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor Branch, Puncak Alam Campus 42300, Selangor, Malaysia.
ORCID-Profile: Anjana Shenoy, Adithya Mysore Shivakumar, Gouri Nair, Mohammed Salim Karattuthodi
Zitieren
APA
Shenoy, A., Mysore Shivakumar, A., Nair, G., Karattuthodi, M. S., Thorakkattil, S. A., & Karuppannan, M. (2025). Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis. International Journal of Pharmacy Practice. https://doi.org/10.1093/ijpp/riaf090
Vancouver
Shenoy A, Mysore Shivakumar A, Nair G, Karattuthodi MS, Thorakkattil SA, Karuppannan M. Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis. International Journal of Pharmacy Practice. 2025. doi:10.1093/ijpp/riaf090
BibTeX
@article{Shenoy2025,
author = {Shenoy, Anjana and Mysore Shivakumar, Adithya and Nair, Gouri and Karattuthodi, Mohammed Salim and Thorakkattil, Shabeer Ali and Karuppannan, Mahmathi},
title = {Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis},
journal = {International Journal of Pharmacy Practice},
year = {2025},
doi = {10.1093/ijpp/riaf090}
}
EUVIMED